News
NBP
2.430
-1.22%
-0.030
NovaBridge Biosciences director Conor Chia-hung Yang files initial beneficial ownership statement
Reuters · 3d ago
Weekly Report: what happened at NBP last week (0323-0327)?
Weekly Report · 5d ago
NovaBridge Biosciences EVP Denny Hsueh Wen Chu Files Initial Beneficial Ownership Statement
Reuters · 03/25 00:08
Weekly Report: what happened at NBP last week (0316-0320)?
Weekly Report · 03/23 10:21
NovaBridge Biosciences CMO Dennis Phillip Andrew Files Initial Beneficial Ownership Statement
Reuters · 03/19 10:18
NovaBridge Biosciences General Counsel Lin Liwei Lorraine Files Initial Beneficial Ownership Statement
Reuters · 03/19 01:45
NovaBridge Biosciences CEO and Director Xi-Yong Fu files Form 3 initial beneficial ownership statement
Reuters · 03/19 01:44
NovaBridge Biosciences files Form 3 reporting Chief Investment Officer Zhang Xiaofan Neo as beneficial owner
Reuters · 03/19 01:41
NovaBridge Biosciences CFO Lei Ming Kyler files initial beneficial ownership statement
Reuters · 03/19 01:40
NovaBridge Biosciences SVP and Head of Operations Joanna Xuqiong Wu files Form 3 initial beneficial ownership statement
Reuters · 03/19 01:39
NovaBridge Biosciences files Form 3 for Chief Business Development Officer and Director Cao Sean Wuxiong
Reuters · 03/19 01:38
NovaBridge Biosciences Director Fu Wei Files Initial Beneficial Ownership Statement
Reuters · 03/19 01:38
NovaBridge Biosciences director Emmett Cunningham files initial beneficial ownership statement
Reuters · 03/19 01:36
NovaBridge Biosciences Files Form 3 for SVP of Clinical Development Claire Xu Cong
Reuters · 03/19 01:36
NovaBridge Biosciences Director Liu Xin Files Initial Beneficial Ownership Statement
Reuters · 03/19 01:35
NovaBridge Biosciences files initial beneficial ownership statement for Global Controller Adeline Yi Zhang
Reuters · 03/19 01:32
NovaBridge Biosciences Director Woo Ian Ying Files Initial Beneficial Ownership Statement
Reuters · 03/19 01:31
NovaBridge Biosciences Director Robert A. Lenz Files Initial Beneficial Ownership Statement
Reuters · 03/19 01:26
NovaBridge Biosciences Director Au Chun Kwok Alan Files Initial Beneficial Ownership Statement
Reuters · 03/19 01:25
NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 03/16 16:30
More
Webull provides a variety of real-time NBP stock news. You can receive the latest news about NovaBridge Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.